

VAERS COVID Vaccine Data Show Surge in Reports of Serious Injuries, as 5-Year-Olds Start Getting Shots

By [Megan Redshaw](#)

Global Research, November 15, 2021

[Children's Health Defense](#) 12 November 2021

Region: [USA](#)

Theme: [Science and Medicine](#)

All Global Research articles can be read in 51 languages by activating the “Translate Website” drop down menu on the top banner of our home page (Desktop version).

To receive Global Research’s Daily Newsletter (selected articles), [click here](#).

Visit and follow us on Instagram at [@crg_globalresearch](#).

VAERS data released today by the CDC included a total of 875,653 reports of adverse events from all age groups following COVID vaccines, including 18,461 deaths and 135,400 serious injuries between Dec. 14, 2020, and Nov. 5, 2021.

The Centers for Disease Control and Prevention (CDC) released new data today showing a total of [875,653 adverse events](#) following COVID vaccines were reported between Dec. 14, 2020, and Nov. 5, 2021, to the Vaccine Adverse Event Reporting System (VAERS). VAERS is the primary government-funded system for reporting adverse vaccine reactions in the U.S.


The data included a total of [18,461 reports of deaths](#) — an increase of 383 over the previous week, and [135,400 reports of serious injuries](#), including deaths, during the same time period — up 7,943 compared with the previous week.

Excluding “[foreign reports](#)” to VAERS, [643,957 adverse events](#), including [8,456 deaths](#) and [53,780 serious injuries](#), were reported in the U.S. between Dec. 14, 2020, and Nov. 5, 2021.

[Foreign reports](#) are reports received by U.S. manufacturers from their foreign subsidiaries. Under U.S. Food and Drug Administration (FDA) regulations, if a manufacturer is notified of a foreign case report that describes an event that is both serious and does not appear on the product’s labeling, the manufacturer is required to submit the report to VAERS.

Of the 8,456 U.S. deaths reported as of Nov. 5, [10% occurred](#) within 24 hours of vaccination, [15% occurred](#) within 48 hours of vaccination and [26% occurred](#) in people who experienced an onset of symptoms within 48 hours of being vaccinated.

In the U.S., 427.6 million COVID vaccine doses had been administered as of Nov. 5. This [includes](#): 250 million doses of [Pfizer](#), 162 million doses of [Moderna](#) and 16 million doses of



Every Friday, [VAERS](#) publicizes vaccine injury reports received as of a specified date. Reports submitted to VAERS require further investigation before a causal relationship can be confirmed. Historically, VAERS has been shown to report only [1% of actual vaccine adverse events](#).

Numbers this week do not yet include reports from the authorization of Pfizer's pediatric COVID vaccine for the 5 to 11 age group. Reports [currently in VAERS](#) for children under 12 are due to "product administered to patient of inappropriate age."

During a [meeting](#) on Oct. 26, by the U.S. Food and Drug Administration's vaccine panel, Dr. Jessica Rose, a viral immunologist and biologist, said tens of thousands of reports have been submitted to the Vaccine Adverse Event Reporting System for children ages 0 to 18, and that 60 children have died — 23 of them were under 2 years old.

"It is disturbing to note that "product administered to patients of inappropriate age was filed 5,510 times in this age group," Rose said. Two children were inappropriately injected, presumably by a trained medical professional, and subsequently died. This is malfeasance."

This week's U.S. data for 12- to 17-year-olds show:

- [22,782](#) total adverse events, including [1,400 rated as serious](#) and [29 reported deaths](#). Two of the 29 deaths were suicides.

The most recent death includes a 17-year-old female from Washington (VAERS ID [1828901](#)) who reportedly died Oct. 29 from a heart condition after receiving her second dose of Pfizer. According to the VAERS report, the girl had COVID in August and fully recovered. She received her first dose of Pfizer on Sept. 3 and her second dose on Sept 15.

On Oct. 23, she presented to the ER with chest pain and elevated troponin. She had an abnormal echocardiogram, abnormal EKG and became increasingly tachycardic. She then suffered cardiac arrest.

“Unfortunately she was not able to be resuscitated and died,” the report states. “Cause of death possible acute myocarditis.”

Other deaths include a 12-year-old girl from South Carolina (VAERS I.D. [1784945](#)) who hemorrhaged 22 days after receiving Pfizer’s COVID vaccine, a 13-year-old girl from Maryland (VAERS I.D. [1815096](#)) who died from a heart condition 15 days after receiving her first dose of Pfizer’s vaccine and a 17-year-old female from Texas (VAERS I.D. [1815295](#)) who experienced an acute [hyperglycemic crisis](#) 33 days after being vaccinated.

- [59 reports](#) of anaphylaxis among 12- to 17-year-olds where the reaction was life-threatening, required treatment or resulted in death — with 96% of cases attributed to [Pfizer’s vaccine](#).
- [552 reports](#) of myocarditis and pericarditis (heart inflammation) with [542 cases](#) attributed to Pfizer’s vaccine.
- [131 reports](#) of blood clotting disorders, with all cases attributed to Pfizer.

This week’s U.S. VAERS data, from Dec. 14, 2020, to Nov. 5, 2021, for all age groups combined, show:

- 19% of deaths were related to cardiac disorders.
- 54% of those who died were male, 42% were female and the remaining death reports did not include gender of the deceased.
- The [average age](#) of death was 72.7.
- As of Nov. 5, [4,260 pregnant women](#) reported adverse events related to COVID vaccines, including 1,337 reports of [miscarriage or premature birth](#).
- Of the [3,123 cases of Bell’s Palsy](#) reported, 51% were attributed to [Pfizer](#) vaccinations, 41% to [Moderna](#) and 8% to [J&J](#).
- 723 reports of [Guillain-Barré syndrome](#) (GBS), with 41% of cases [attributed to Pfizer](#), 30% to [Moderna](#) and 28% to [J&J](#).
- [2,093 reports](#) of anaphylaxis where the reaction was life-threatening, required treatment or resulted in death.
- [10,857 reports](#) of blood clotting disorders. Of those, [4,790 reports](#) were attributed to Pfizer, [3,864 reports](#) to Moderna and [2,149 reports](#) to J&J.
- [3,071 cases](#) of myocarditis and pericarditis with [1,922 cases](#) attributed to Pfizer, [1,016 cases](#) to Moderna and [123 cases](#) to J&J’s COVID vaccine.

Teen diagnosed with Guillain-Barré syndrome After COVID Vaccine

A 17-year-old girl was [hospitalized for Guillain-Barré syndrome](#) (GBS) — a [rare disorder](#) in which the body’s immune system attacks its nerves — after receiving a COVID vaccine. Shelby Allen said she’s thankful she isn’t paralyzed and didn’t die.

Shelby Allen, a 17-year-old from Dyer County, Tennessee, is hospitalized with a rare disorder in which the body's immune system attacks its nerves. She developed the condition after getting a COVID vaccine.

SIGN UP [#TheDefender](https://t.co/zL66Edfiw5): <https://t.co/zL66Edfiw5><https://t.co/M2wxPUxn3X>

— Robert F. Kennedy Jr (@RobertKennedyJr) [November 10, 2021](#)

Allen started [experiencing back pain](#) and tingling in her arms after getting vaccinated. Symptoms progressed until she found herself unable to feel her arms and legs while bowling with her school's team. Allen's parents took her to the doctor in Jackson, Tennessee, where she was diagnosed with GBS and admitted to the ICU.

Allen's doctor "knew right off the bat" her reaction was caused by a COVID vaccine, but still recommended people get vaccinated. Allen is hoping she'll be able to walk by March for her high school graduation.

Taiwan temporarily halts second dose of Pfizer over myocarditis concerns

The Central Epidemic Command Center (CECC) said on Wednesday a panel of experts is [suspending second doses](#) of Pfizer-BioNTech's COVID vaccine for children 12 to 17 years old amid concerns it may increase the risk of [myocarditis](#).

Cases of myocarditis (inflammation of the heart muscle) and pericarditis (inflammation of the outer lining of the heart) have been reported in children between 12 and 17 years old who received Pfizer's vaccine.

CECC cited U.S. statistics which show the risk of experiencing heart inflammation after receiving a second dose is 10 times higher than after the first dose.

Chen Shih-chung, who heads up the CECC, said the Ministry of Health and Welfare's Advisory Committee for Immunization Practices halted second doses of Pfizer for two weeks, during which time experts and CDC physicians will assess 16 cases of myocarditis among adolescents after Pfizer vaccination before making a decision on whether to go ahead with the second dose.

Hong Kong gives only a single dose to teens 12 to 17, while the UK recommends only one shot for children between ages 12 and 18.

More countries restrict Moderna vaccine over reports of myocarditis

France's public health authority recommended people under 30 receive Pfizer's COVID vaccine instead of Moderna, due to higher risks of heart problems in young adults, [Reuters reported](#).

The Haute Autorite de Sante (HAS), an independent advisor to the French health sector, cited "very rare" risks linked to myocarditis, confirmed by a French study published Monday.

"Within the population aged under 30, this risk appears to be around five times lesser with [Pfizer's Comirnaty](#) jab compared to Moderna's Spikevax jab," HAS said.

Germany's advisory committee, known as STIKO, said on Wednesday [people under age 30](#)

should receive only Pfizer's vaccine, as it causes fewer cases of heart inflammation in younger people. STIKO also recommended pregnant women receive only the Pfizer vaccine, regardless of their age.

The recommendations were based on new safety data from the Paul Ehrlich Institute — Germany's authority in charge of vaccines, and new data.

The decision came after several other countries [restricted the use of Moderna](#) to older populations, including Canada, Finland, [Denmark and Sweden](#). France's medical regulator on Oct. 15 [recommended](#) using only Pfizer's vaccine for booster shots, despite the European Union's drug regulator last month [approving Moderna's booster](#) for all age groups over 18.

Pfizer asks FDA to authorize third booster dose for all people 18 and older

As [The Defender reported](#) Nov. 10, Pfizer and BioNTech on Tuesday asked the FDA to authorize a third dose of their COVID vaccine for all people 18 and older, even though advisory panels to the FDA and CDC in September [overwhelmingly rejected](#) a similar request.

The companies said their new request is based on the [results of a study](#), conducted by Pfizer and BioNTech, which has not been [published or peer-reviewed](#). The companies said the study of more than 10,000 volunteers showed vaccine efficacy against symptomatic infection of 95% or greater for people receiving the booster.

Pfizer did not disclose how many participants experienced asymptomatic infection, or whether the clinical trial — as did Pfizer's [clinical trial for 5 to 11 years olds](#) — included individuals with [natural immunity](#) acquired from previous SARS-CoV-2 infection.

[Children's Health Defense](#) asks anyone who has experienced an adverse reaction, to any vaccine, to file a report following [these three steps](#).

*

Note to readers: Please click the share buttons above or below. Follow us on Instagram, @crg_globalresearch. Forward this article to your email lists. Crosspost on your blog site, internet forums. etc.

Megan Redshaw is a freelance reporter for The Defender. She has a background in political science, a law degree and extensive training in natural health.

Featured image is from CHD

The original source of this article is [Children's Health Defense](#)
Copyright © [Megan Redshaw](#), [Children's Health Defense](#), 2021

[Comment on Global Research Articles on our Facebook page](#)

[Become a Member of Global Research](#)

Articles by: [Megan Redshaw](#)

Disclaimer: The contents of this article are of sole responsibility of the author(s). The Centre for Research on Globalization will not be responsible for any inaccurate or incorrect statement in this article. The Centre of Research on Globalization grants permission to cross-post Global Research articles on community internet sites as long the source and copyright are acknowledged together with a hyperlink to the original Global Research article. For publication of Global Research articles in print or other forms including commercial internet sites, contact: publications@globalresearch.ca

www.globalresearch.ca contains copyrighted material the use of which has not always been specifically authorized by the copyright owner. We are making such material available to our readers under the provisions of "fair use" in an effort to advance a better understanding of political, economic and social issues. The material on this site is distributed without profit to those who have expressed a prior interest in receiving it for research and educational purposes. If you wish to use copyrighted material for purposes other than "fair use" you must request permission from the copyright owner.

For media inquiries: publications@globalresearch.ca